Lm. Rosser et al., IN-VITRO PROTEIN-BINDING CHARACTERISTICS OF ATEVIRDINE AND ITS N-DEALKYLATED METABOLITE, Antiviral research, 25(3-4), 1994, pp. 193-200
The in vitro protein-binding characteristics of atevirdine (ATV), a no
n-nucleoside reverse transcriptase inhibitor with activity against HIV
-1, and its N-dealkylated metabolite (N-ATV) were studied using equili
brium dialysis. ATV and N-ATV were studied at concentrations of 5, 10,
20, and 30 mu M in five protein-containing solutions [albumin 4%, pla
sma, serum, immune globulin (IgG) 1.5%, alpha(1)-acid glycoprotein (AA
G)] for 5 h at 37 degrees C. All samples were analyzed by high-perform
ance liquid chromatography. The free fraction of atevirdine in plasma,
albumin, and serum was 0.01-0.02 over the range of drug concentration
s studied. The fraction unbound (f(u)) in these protein solutions stat
istically differed from IgG and AAG (P < 0.05), where the fraction unb
ound averaged 0.96 and 0.53, respectively. N-ATV had a similar binding
profile as ATV with a fraction unbound of 0.04, 0.03, 0.03 in albumin
, plasma and serum, respectively. A difference existed in N-ATV bindin
g when compared to IgG and AAG with an average f(u) of 0.87 and 0.59 (
P < 0.05 vs. plasma). The potential clinical implications of the high
degree of protein binding for ATV and N-ATV are discussed.